このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Imunon マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Stacy Lindborg

最高経営責任者

US$44.1k

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	1.2yrs
取締役会の平均在任期間	5.8yrs

経営陣の近況

Recent updates

Celsion changes name to Imunon (IMNN)

Sep 19

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

Sep 01

CEO（最高経営責任者

Stacy Lindborg (53 yo)

less than a year

在職期間

US$44,095

報酬

Dr. Stacy R. Lindborg, Ph D., was Co-Chief Executive Officer of Brainstorm Cell Therapeutics Inc. since January 2023 until May 09, 2024 and serves as its Director since May 09, 2024. Dr. Lindborg joined th...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Michael Tardugno	Executive Chairman	17.4yrs	データなし	0.18% $ 17.5k
Stacy Lindborg	President	less than a year	US$44.10k	データなし
Khursheed Anwer	Executive VP & Chief Scientific Officer	10yrs	US$680.16k	0.030% $ 3.0k
David Gaiero	Chief Financial Officer	no data	データなし	データなし
Timothy Tumminello	Chief Accounting Officer & Controller	14.4yrs	US$137.75k	データなし
Sebastien Hazard	Executive VP & Chief Medical Officer	less than a year	データなし	0.21% $ 21.2k

1.2yrs

平均在職期間

58.5yo

平均年齢

経験豊富な経営陣: IMNNの経営陣は経験豊富とはみなされません ( 1.2年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Michael Tardugno	Executive Chairman	17.4yrs	データなし	0.18% $ 17.5k
Stacy Lindborg	President	3yrs	US$44.10k	データなし
Christine Pellizzari	Independent Director	3yrs	US$47.70k	0% $ 0
Wafik El-Deiry	Member of Advisory Board	no data	データなし	データなし
David Cheresh	Member of Advisory Board	no data	データなし	データなし
Michael Weinblatt	Member of Advisory Board	no data	データなし	データなし
James Dentzer	Independent Director	1.8yrs	US$61.20k	0% $ 0
Frederick Fritz	Independent Director	12.9yrs	US$106.20k	0.13% $ 12.5k
Jerry Glickson	Member of Advisory Board	no data	データなし	データなし
Mark Dewhirst	Member of Advisory Board	no data	データなし	データなし
Peter Corry	Member of Advisory Board	no data	データなし	データなし
Donald Braun	Independent Director	8.5yrs	US$72.90k	0.0063% $ 632.8

5.8yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: IMNNの取締役会は経験豊富であると考えられます ( 5.8年の平均在任期間)。

Imunon マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

Recent updates

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

Price target decreased by 17% to US$10.00

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New minor risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

New minor risk - Share price stability

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Consensus EPS estimates upgraded to US$2.95 loss

Price target decreased by 19% to US$18.75

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Price target decreased to US$24.00

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion changes name to Imunon (IMNN)

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

First half 2022 earnings: EPS and revenues exceed analyst expectations

Celsion Q2 2022 Earnings Preview

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion adds Moderna chief commercial officer as CEO

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Celsion Corporation, Annual General Meeting, Jun 13, 2022

Price target decreased to US$32.67

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $7.000004 million.

Price target decreased to US$41.00

Full year 2021 earnings: EPS misses analyst expectations

Celsion Corporation Reports Impairment for the Fourth Quarter Ended December 31, 2021

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Celsion Corporation announced that it expects to receive $28.5 million in funding

Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?

Third quarter 2021 earnings released: US$0.063 loss per share (vs US$0.24 loss in 3Q 2020)

Celsion Corporation Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform

First half 2021 earnings released: US$0.15 loss per share (vs US$0.37 loss in 1H 2020)

Is Celsion (NASDAQ:CLSN) Using Too Much Debt?

Celsion Corporation Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer

Celsion Corporation(NasdaqCM:CLSN) dropped from Russell Microcap Growth Index

First quarter 2021 earnings released: US$0.086 loss per share (vs US$0.20 loss in 1Q 2020)

Full year 2020 earnings released: US$0.67 loss per share (vs US$0.77 loss in FY 2019)

Celsion Corporation Announces Update on Phase I/II Ovation 2 Study

Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores

Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (Nol) Program

Price target raised to US$4.00

マネジメント基準チェック /34